Federal Drug Strategy--1983


Book Description













Federal Regulation of Methadone Treatment


Book Description

For nearly three decades, methadone hydrochloride has been the primary means of treating opiate addiction. Today, about 115,000 people receive such treatment, and thousands more have benefited from it in the past. Even though methadone's effectiveness has been well established, its use remains controversial, a fact reflected by the extensive regulation of its manufacturing, labeling, distribution, and use. The Food and Drug Administration regulates the safety and effectiveness of methadone, as it does for all drugs, and the Drug Enforcement Administration regulates it as a controlled substance. However, methadone is also subjected to a unique additional tier of regulation that prescribes how and under what circumstances it may be used to treat opiate addiction. Federal Regulation of Methadone Treatment examines current Department of Health and Human Services standards for narcotic addiction treatment and the regulation of methadone treatment programs pursuant to those standards. The book includes an evaluation of the effect of federal regulations on the provision of methadone treatment services and an exploration of options for modifying the regulations to allow optimal clinical practice. The volume also includes an assessment of alternatives to the existing regulations.




America's Drug Strategy


Book Description

Excerpt from America's Drug Strategy: Lessons of the Past Steps Toward the Future: Hearing Before the Committee on the Judiciary, United States Senate, One Hundred Third Congress, on Examining the National Drug Control Policy, Focusing on Law Enforcement, Drug Treatment and Prevention Programs, April 29, 1993 U.S. Senate, Committee on the Judiciary, Washington, DC. The committee met, pursuant to notice, at 10:22 a.m., in room Sd-226, Dirksen Senate Office Building, Hon. Joseph R.Biden, Jr. (chairman of the committee) presiding. Also present: Senators Metzenbaum, Feinstein, Moseley-Braun, Hatch, Grassley, Specter, and Pressler. Opening Statement Of Hon. Joseph R.Biden, Jr., A U.S. Senator From The State Of Delaware The Chairman. The hearing will come to order. Today we are beginning the first of what will be a series of hearings on our national drug strategy, and today I am releasing the fourth annual Comprehensive National Drug Strategy, which in years past was referred to as an alternative strategy. This year's strategy shares the primary goal of all others, and that is gaining control of the drug epidemic. At the same time, this years strategy stands apart from those offered in the past. Quite simply, we face a unique moment of opportunity in two respects. First, 4 years into the fight the Nation has some hard lessons about what works and what does not in determining how to deal with deterring drug addiction and drug-related crime. Second, with a new President we hopefully will have very shortly a new drug Director, a man who I think most of us would conclude is a first-rate, serious player. The time is ripe to take advantage of the lessons we have learned in the past, the mistakes in strategy made by the last administration, made by me, made by the Congress, made by all of us, to move with a consensus toward a new drug strategy. Since the release of the first annual drug strategy in September 1989, the Federal Government has spent a total of $38.5 billion combating the drug epidemic. Unfortunately, these enormous expenditures have not won the war. Hard-core drug addiction, drug-fueled crime and violence, and drug supplies have, in fact, worsened since the release of the first drug strategy. For example, there are currently about 6 million hard-core addicts. There is a drug treatment shortfall of at least 900, 000 treatable hard-core addicts. Comprehensive drug education programs barely reach one in every two school children in America. About the Publisher Forgotten Books publishes hundreds of thousands of rare and classic books. Find more at www.forgottenbooks.com This book is a reproduction of an important historical work. Forgotten Books uses state-of-the-art technology to digitally reconstruct the work, preserving the original format whilst repairing imperfections present in the aged copy. In rare cases, an imperfection in the original, such as a blemish or missing page, may be replicated in our edition. We do, however, repair the vast majority of imperfections successfully; any imperfections that remain are intentionally left to preserve the state of such historical works.




Rare Diseases and Orphan Products


Book Description

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.




Treating Drug Problems:


Book Description

Treating Drug Problems, Volume 2 presents a wealth of incisive and accessible information on the issue of drug abuse and treatment in America. Several papers lay bare the relationship between drug treatment and other aspects of drug policy, including a powerful overview of twentieth century narcotics use in America and a unique account of how the federal government has built and managed the drug treatment system from the 1960s to the present. Two papers focus on the criminal justice system. The remaining papers focus on Employer policies and practices toward illegal drugs. Patterns and cycles of cocaine use in subcultures and the popular culture. Drug treatment from a marketing, supply-and-demand perspective, including an analysis of policy options. Treating Drug Problems, Volume 2 provides important information to policy makers and administrators, drug treatment specialists, and researchers.




Risk Assessment in the Federal Government


Book Description

The regulation of potentially hazardous substances has become a controversial issue. This volume evaluates past efforts to develop and use risk assessment guidelines, reviews the experience of regulatory agencies with different administrative arrangements for risk assessment, and evaluates various proposals to modify procedures. The book's conclusions and recommendations can be applied across the entire field of environmental health.




The American Disease


Book Description

The American Disease is a classic study of the development of drug laws in the United States. Supporting the theory that Americans' attitudes toward drugs have followed a cyclic pattern of tolerance and restraint, author David F. Musto examines the relationz between public outcry and the creation of prohibitive drug laws from the end of the Civil War up to the present. Originally published in 1973, and then in an expanded edition in 1987, this third edition contains a new chapter and preface that both address the renewed debate on policy and drug legislation from the end of the Reagan administration to the current Clinton administration. Here, Musto thoroughly investigates how our nation has dealt with such issues as the controversies over prevention programs and mandatory minimum sentencing, the catastrophe of the crack epidemic, the fear of a heroin revival, and the continued debate over the legalization of marijuana.